N-Ethyl-N-Methylcarbamoyl Chloride CAS 42252-34-6 Rivastigmine Tartrate Intermediate Purity >99.0% (GC)

N-Ethyl-N-Methylcarbamoyl Chloride (Ethyl(methyl)carbamic Chloride) (CAS: 42252-34-6), intermediate of Rivastigmine Tartrate (CAS: 129101-54-8). Rivastigmine Tartrate is the tartrate of rivastigmine, a drug for the treatment of Alzheimer's disease. Rivastigmine is a physostigmine derivative, which was successfully developed for the first time by Novartis, Switzerland. The trade name is exelon, and the molecule has a benzyl carbamate structure, it is a carbamate brain-selective cholinesterase inhibitor, which can inhibit acetylcholinesterase and butyrylcholinesterase at the same time, and promote cholinergic nerve conduction by delaying the degradation of acetylcholine released by cholinergic neurons. It can improve the cognitive dysfunction mediated by cholinergic, thereby improving the cognitive effect of patients with Alzheimer's disease. The plasma protein binding capacity of rivastigmine is weak, easy to pass through the blood-brain barrier, and has a high degree of brain selectivity. It can not only selectively act on the most vulnerable areas of the cerebral cortex and hippocampus, but also preferentially inhibit the dominant subtypes of AChE in the brain, which can reduce peripheral cholinergic side effects while producing curative effects. The half-life of rivastigmine tartrate in the body is short and the action time is long. Unlike tacrine, this product has a stronger inhibitory effect on G1 enzyme in the hippocampus and cortex. It is clinically used to treat mild to moderate Alzheimer's dementia, which is suspected of Alzheimer's disease or Alzheimer's disease.